ATE526966T1 - Flüssige formulierungen von salzen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin - Google Patents

Flüssige formulierungen von salzen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin

Info

Publication number
ATE526966T1
ATE526966T1 AT08715616T AT08715616T ATE526966T1 AT E526966 T1 ATE526966 T1 AT E526966T1 AT 08715616 T AT08715616 T AT 08715616T AT 08715616 T AT08715616 T AT 08715616T AT E526966 T1 ATE526966 T1 AT E526966T1
Authority
AT
Austria
Prior art keywords
phenylupiperidine
methylphenylsulfanyl
salts
liquid formulations
formulations
Prior art date
Application number
AT08715616T
Other languages
English (en)
Inventor
Gudrun Lasskogen
Tine Stensbyl
De Diego Heidi Lopez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2007/050076 external-priority patent/WO2007144006A1/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE526966T1 publication Critical patent/ATE526966T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT08715616T 2007-03-20 2008-03-14 Flüssige formulierungen von salzen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin ATE526966T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200700423 2007-03-20
PCT/DK2007/050076 WO2007144006A1 (en) 2006-06-16 2007-06-15 Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
US1391807P 2007-12-14 2007-12-14
DKPA200701790 2007-12-14
PCT/DK2008/050062 WO2008113358A1 (en) 2007-03-20 2008-03-14 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine

Publications (1)

Publication Number Publication Date
ATE526966T1 true ATE526966T1 (de) 2011-10-15

Family

ID=39327217

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08715616T ATE526966T1 (de) 2007-03-20 2008-03-14 Flüssige formulierungen von salzen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin

Country Status (27)

Country Link
US (1) US20100105730A1 (de)
EP (2) EP2129377B1 (de)
JP (1) JP5301474B2 (de)
KR (1) KR20090130000A (de)
AR (1) AR065796A1 (de)
AT (1) ATE526966T1 (de)
AU (1) AU2008228637B2 (de)
BR (1) BRPI0808820A2 (de)
CA (1) CA2684592C (de)
CL (1) CL2008000797A1 (de)
CO (1) CO6220958A2 (de)
CY (1) CY1112285T1 (de)
DK (1) DK2129377T3 (de)
EA (1) EA019695B1 (de)
ES (1) ES2373275T3 (de)
HK (1) HK1140949A1 (de)
HR (1) HRP20110844T1 (de)
IL (1) IL200959A (de)
MX (1) MX2009009388A (de)
MY (1) MY148695A (de)
NZ (1) NZ579717A (de)
PL (1) PL2129377T3 (de)
PT (1) PT2129377E (de)
RS (1) RS52050B (de)
SI (1) SI2129377T1 (de)
TW (1) TWI405588B (de)
WO (1) WO2008113358A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI432194B (zh) 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
WO2008151632A1 (en) * 2007-06-15 2008-12-18 H.Lundbeck A/S 4- [2- (4-methylphenylsulfanyl) phenyl] piperidine for the treatment of irritable bowel syndrome (ibs)
MX2011011119A (es) * 2009-04-24 2011-11-04 Lundbeck & Co As H Formulaciones liquidas de sales de 1-[2-(2,4-dimetilfenilsulfanil) fenil] piperazina.
MA34261B1 (fr) 2010-04-30 2013-05-02 Takeda Pharmaceutcal Company Ltd Comprime a delitage intestinal
GEP20166487B (en) 2010-04-30 2016-06-10 Takeda Pharmaceutical Enteric tablet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10163326A1 (de) 2001-07-30 2003-02-27 Disetronic Licensing Ag Verabreichungsgerät mit Dosiervorrichtung
UA81749C2 (uk) * 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP4405802B2 (ja) 2001-10-16 2010-01-27 メディカル・インスティル・テクノロジーズ・インコーポレイテッド 計量された量の物質を供給するための、密閉チャンバ及び一方向弁を備えたディスペンサ
DE10202367A1 (de) 2002-01-23 2003-09-25 Duerr Dental Gmbh Co Kg Applikator für flüssige oder viskose Substanzen
AU2004226838B8 (en) * 2003-04-04 2009-06-11 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
EA016054B1 (ru) * 2006-06-16 2012-01-30 Х. Лундбекк А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)фенил] пиперидина с объединенным ингибированием повторного поглощения серотонина и норадреналина для лечения невропатической боли
KR101367136B1 (ko) * 2007-07-27 2014-02-25 삼성디스플레이 주식회사 유기 발광 표시 장치 및 이의 제조 방법

Also Published As

Publication number Publication date
TWI405588B (zh) 2013-08-21
HRP20110844T1 (hr) 2011-12-31
MX2009009388A (es) 2009-11-25
EP2129377B1 (de) 2011-10-05
AU2008228637A1 (en) 2008-09-25
EA019695B1 (ru) 2014-05-30
WO2008113358A1 (en) 2008-09-25
PT2129377E (pt) 2011-12-23
SI2129377T1 (sl) 2012-01-31
CO6220958A2 (es) 2010-11-19
BRPI0808820A2 (pt) 2014-08-19
EA200970869A1 (ru) 2010-02-26
IL200959A0 (en) 2010-05-17
ES2373275T3 (es) 2012-02-01
AU2008228637B2 (en) 2013-03-21
EP2129377A1 (de) 2009-12-09
HK1140949A1 (en) 2010-10-29
PL2129377T3 (pl) 2012-02-29
JP5301474B2 (ja) 2013-09-25
JP2010521500A (ja) 2010-06-24
CA2684592A1 (en) 2008-09-25
MY148695A (en) 2013-05-31
NZ579717A (en) 2012-06-29
US20100105730A1 (en) 2010-04-29
KR20090130000A (ko) 2009-12-17
CY1112285T1 (el) 2015-12-09
RS52050B (en) 2012-04-30
TW200902083A (en) 2009-01-16
DK2129377T3 (da) 2012-01-02
EP2388004A1 (de) 2011-11-23
IL200959A (en) 2011-12-29
AR065796A1 (es) 2009-07-01
CL2008000797A1 (es) 2008-09-26
CA2684592C (en) 2013-11-12

Similar Documents

Publication Publication Date Title
DK2238985T3 (da) Højkoncentreret antistofholdig væskeformulering
BRPI0821474A2 (pt) formulação farmacêutica líquida estável
BRPI0910515A2 (pt) composição líquida
BRPI0922904A2 (pt) "compostos"
DK2219607T3 (da) Flydende LH-formuleringer
DK2789349T3 (da) Flydende præparat omfattende pimobendan
DK2185142T3 (da) Antiseptiske midler
DK3103456T3 (da) Dialysevæskesammensætning, der omfatter krystalliseringsinhibitorsubstanser
ATE519836T1 (de) Flüssige weissgraderhaltungszusammensetzung
DE602007000495D1 (de) Flüssigkeit-Koinfusionsgerät
BR112013010684A2 (pt) "composição de surfactante líquida"
DK2966175T3 (da) Farmaceutiske sammensætninger indeholdende cortexolon-17-alpha-propionat
BRPI0719514A2 (pt) Preparações líquidas aquosas compreendendo gatifloxacina
DK2197919T3 (da) Flydende formulering af g-csf-konjugat
ATE477712T1 (de) Flüssigformulierung von pyrethroiden
ATE526966T1 (de) Flüssige formulierungen von salzen von 4-ä2-(4- methylphenylsulfanyl)phenylüpiperidin
DK2173197T3 (da) Fremgangsmåde
DK2182920T3 (da) Stabil væskeformig farmaceutisk komposition baseret på trazodon
NO20070960A (no) Teine
DK2076243T3 (da) Væskeformulering af G-CSF
SMT201500123B (it) Dosaggio unitario di apadenoson
BRPI0913709A2 (pt) "formulação farmacêutica"
DK2269517T3 (da) Væskeapplikator
BRPI0913347A2 (pt) modificações estáveis de cristais de dopc
BRPI0822199A2 (pt) Formulação herbicida

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2129377

Country of ref document: EP